INFLIXIMAB TROUGH LEVELS AND DISEASE ACTIVITY PREDICT EARLY CLINICAL RESPONSE IN PATIENTS WITH AXIAL SPONDYLOARHTRITIS

被引：2

作者：

Martinez-Feito, Ana ^{[1
]}

Plasencia, Chamaida ^{[2
]}

Hernandez-Breijo, Borja ^{[3
]}

Navarro-Compan, Victoria ^{[2
]}

Peiteado, Diana ^{[2
]}

Villalva, Alejandro ^{[2
]}

Nuno, Laura ^{[2
]}

Monjo, Irene ^{[2
]}

Diego, Cristina ^{[1
]}

Pascual-Salcedo, Dora ^{[3
]}

Balsa, Alejandro ^{[2
]}

机构：

[1] Hosp La Paz Madrid, Immunol, Madrid, Spain

[2] Hosp La Paz Madrid, Rheumatol, Madrid, Spain

[3] IdiPAZ, Immunorheumatol Res Grp, Madrid, Spain

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷

关键词：

D O I：

10.1136/annrheumdis-2019-eular.3984

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

FRI0399

引用

页码：885 / 885

页数：1

共 50 条

[31] LOW LEVELS OF INFLIXIMAB AT EARLY STAGES PREDICT THE LOSS OF DRUG LEVELS AND THE CLINICAL RESPONSE AT ONE YEAR OF TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS
Jurado, T.
Plasencia, C.
Martinez-Feito, A.
Navarro-Compan, V.
Olariaga, E.
Diego, C.
Martin-Mola, E.
Balsa, A.
Pascual-Salcedo, D.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 490 - 490
[32] Infliximab Low Levels at Early Stages Predict the Loss of Drug Levels and the Clinical Response at One Year of Treatment in Patients with Rheumatoid Arthritis
Jurado, Teresa
Plasencia-Rodriguez, Chamaida
Martinez, Ana
Navarro-Colmpan, Victoria
Olariaga-Merida, Eva
Peiteado, Diana
Villalba, Alejandro
Bonilla, Gema
Diego, Cristina
Balsa, Alejandro
Pascual-Salcedo, Dora
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[33] LOSS OF RESPONSE IN IBD PATIENTS ON INFLIXIMAB TREATMENT: ASSAY OF TROUGH LEVELS AND TOTAL ANTIBODIES TO INFLIXIMAB
Marzo, M.
Armuzzi, A.
Tolusso, B.
Pugliese, D.
Felice, C.
Andrisani, G.
Landi, R.
Canestri, S.
Gremese, E.
Papa, A.
Rapaccini, G.
Guidi, L.
DIGESTIVE AND LIVER DISEASE, 2015, 47 : E177 - E177
[34] Infliximab Dosing for Patients With Inflammatory Bowel Disease, Based on Trough Levels
Lowe, Anson W.
Moseley, Richard H.
GASTROENTEROLOGY, 2015, 148 (07) : 1261 - 1261
[35] Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease
Hanzel, Jurij
Sever, Nejc
Ferkolj, Ivan
Stabuc, Borut
Smrekar, Natasa
Kurent, Tina
Kozelj, Matic
Novak, Gregor
Compernolle, Griet
Tops, Sophie
Gils, Ann
Drobne, David
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2019, 7 (06) : 741 - 749
[36] Infliximab trough levels are decreasing overtime in patients with inflammatory bowel disease on maintenance treatment with infliximab
Orfanoudaki, E.
Gazouli, M.
Foteinogiannopoulou, K.
Theodouraki, E.
Legaki, E.
Koutroubakis, I.
JOURNAL OF CROHNS & COLITIS, 2018, 12 : S330 - S331
[37] Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn's Disease
Orts, Beatriz
Gutierrez, Ana
Madero, Lucia
Sempere, Laura
Frances, Ruben
Zapater, Pedro
FRONTIERS IN PHARMACOLOGY, 2022, 12
[38] Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
Choi, So Yoon
Kang, Ben
Lee, Jee Hyun
Choe, Yon Ho
GUT AND LIVER, 2017, 11 (01) : 55 - 61
[39] Baseline tumor necrosis factor alpha levels predict the clinical response of infliximab therapy in patients with crohn's disease
Nomura, Eiki
Sato, Takeshi
Kannno, Nana
Sakuta, Kazuhiro
Mizumoto, Naoko
Shibuya, Rika
Yagi, Makoto
Iwano, Daisuke
Sasaki, Yu
Abe, Yasuhiko
Nishise, Syoichi
Ueno, Yoshiyuki
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 131 - 131
[40] Infliximab trough levels and anti-drug antibodies after induction predict long-term clinical remission in infliximab-treated patients with inflammatory bowel disease
Bodini, G.
Del Nero, L.
Giannini, E. G.
Tolone, S.
De Bortoli, N.
Anjali, J.
Baldissarro, I.
Savarino, V.
Savarino, E.
JOURNAL OF CROHNS & COLITIS, 2016, 10 : S408 - S409

← 1 2 3 4 5 →